KYNTRA BIO INC
KYNBNASDAQ🏆 #4630 by market capEarnings Nov 9 · PostUS Equity
$4.70▲ $0.20 (+4.44%)
Pre-market · at closeTrack KYNB
Get earnings, price moves & breaking news on Telegram
24h▲ 4.4%
7d▼ 10.0%
14d▼ 16.8%
30d▼ 35.2%
ytd▼ 46.3%
1y▼ 56.6%
🏦Market Cap
$19M
Small Cap
📈Revenue Growth (YoY)
-91.4%
Declining
📊Gross Margin
40.7%
Healthy
💵FCF Margin
333.0%
Strong
⚖️P/S Ratio
3.9x
Fair
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $4.67 – $4.70
- 52-Week Range
- $4.32 – $11.39
- Volume (shares)
- 412
- Avg Volume (shares)
- —
- Shares Outstanding
- 4.0M
- Next Earnings
- 2026-11-09
Fundamentals Snapshot
- Annual Revenue
- $6M
- Last Q Revenue
- —
- P/E Ratio
- 0.1
- P/S Ratio
- 3.9x
- EPS (TTM)
- $45.30
- Dividend Yield
- —
- Dilution (1yr)
- +0.2%
KYNTRA BIO INC
KYNBFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$6M▼ −78.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
91.4%▲ +92.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$46M▼ −69.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$5M▼ −96.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
4.0M▲ +0.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$48M▲ +$70M YoY
StockOtter · stockotter.spaceAbout KYNTRA BIO INC
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
10 analysts
Strong Buy3
Buy5
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.